Cellistic acquires Artisan Bio’s technology platform, bolstering its gene editing, cell therapy development and manufacturing offerings

299

0 comment

Staff at TrialSite | Quality Journalism

Apr. 14, 2024, 1:00 a.m.

Belgium-based Cellistic, a company specializing in process development and manufacture of immune cell therapies based on human induced pluripotent stem cell (iPSC) technology, announced the acquisition of the full Artisan Bio technology platform, including the STAR-CRISPR Cas-12 gene editing technology, as well as a full IP portfolio.

Cellistic said the acquired assets will bolster its gene editing platform capabilities and expand its presence in the induced pluripotent stem cells (iPSC) allogenic cell therapy development and manufacturing space.

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month
which is less than a Starbucks coffee!

Peter Gabriel, MD

"Publishing on TrialSite helped me secure a $20m research grant for my work."

Jona Savinda

"TrialSiteNews is my daily read for what is happening in the industry."